Induced pluripotent stem cells, organs-on-a-chip and an integrated network of patient-focused practices for streamlined research have launched a new era of cancer innovation at Cedars-Sinai. By bringing together experts in regenerative medicine, fluid dynamics, the tumor microenvironment, single-cell sequencing, bioinformatics and multiple subspecialties in clinical oncology, Cedars-Sinai has begun validating new methods to provide actionable information on cancer development, prevention and treatment.
“We are focused on making sure that we have a good representation of mutation carriers from other ethnic groups, specifically our Los Angeles-based Korean population, Mexican-heritage Latinx people, Ashkenazi Jewish community and Black patients, all of whom may carry unique BRCA-germline mutations.”
– Bobbie J. Rimel, MD
A New BRCA Screening Tool
Organoids made from induced pluripotent stem cells coupled with chip techniques hold tremendous potential as a complementary risk metric and preclinical drug-screening tool for people with BRCA mutations. Mutations in the BRCA1 and BRCA2 genes predispose patients of both sexes to several cancers, such as ovarian, breast, pancreas and prostate, all of which are major areas of focus at Cedars-Sinai. They may also help illuminate the origins of sporadic cancer development.
To advance these promising technologies, Cedars-Sinai now offers multipurpose visits in programs such as the new BRCA previvor multidisciplinary clinic. In a single, coordinated visit, the clinic provides patients with personalized screening and care as well as information on opportunities for research participation—enabling research into BRCA-driven cancers. That also addresses issues driving health disparity.
Why diversity matters in cancer clinical trials.